Gilead Sciences (FRA:GIS) Float Percentage Of Total Shares Outstanding: 99.92% (As of Jul. 07, 2026)


FRA:GIS Gilead Sciences Inc FRA:GIS
69 GF Score
Price €112.82
GF Value €82.35
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Float Percentage Of Total Shares Outstanding?

Gilead Sciences FRA:GIS -1.79% 69 Float Percentage Of Total Shares Outstanding is 99.92% as of Jul. 07, 2026. GuruFocus rates FRA:GIS with a GF Score™ of 69/100 and a GF Value™ of €82.35 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Gilead Sciences's float shares is 1,240.52 Mil. Gilead Sciences's total shares outstanding is 1,241.57 Mil. Gilead Sciences's float percentage of total shares outstanding is 99.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Gilead Sciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Gilead Sciences's Institutional Ownership is 69.50%.

FRA:GIS
69GF Score
Gilead Sciences Inc FRA:GIS
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Gilead Sciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=1,240.52/1,241.57
=99.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 99.92% mean?
Gilead Sciences (FRA:GIS) has a Float Percentage Of Total Shares Outstanding of 99.92% as of Jul. 07, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Float Percentage Of Total Shares Outstanding too high?
Gilead Sciences' current Float Percentage Of Total Shares Outstanding is 99.92%. Overall, Gilead Sciences has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Float Percentage Of Total Shares Outstanding compare to PFE and AMGN?
Gilead Sciences' Float Percentage Of Total Shares Outstanding of 99.92% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Float Percentage Of Total Shares Outstanding is 99.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.35, compared to a current price of €112.82 — trading 37% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 99.92%. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Float Percentage Of Total Shares Outstanding is 99.92% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €112.82 is trading 37% above its estimated GF Value™ of €82.35. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Float Percentage Of Total Shares Outstanding: 99.92%
  • GF Value™: €82.35 vs. price of €112.82 (37% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score

Get the complete analysis for FRA:GIS

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€112.82
Price
€82.35
GF Value